Description
COMPOSITION: Each capsules contains Palbociclib 125 mg
INDICATION: Indications for use PALBOCICLIB is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer: – in combination with an aromatase inhibitor; – in combination with fulvestrant in women previously receiving endocrine therapy. In pre-or perimenopausal women, endocrine therapy should be combined with aluteinization. Hormone Releasing Hormone (LHRH) agonists.
PACKING: 21 Capsules / Bottle
